{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:08:03Z","timestamp":1761059283085},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2,15]]},"DOI":"10.2146\/ajhp110277","type":"journal-article","created":{"date-parts":[[2012,2,2]],"date-time":"2012-02-02T16:41:29Z","timestamp":1328200889000},"page":"302-306","source":"Crossref","is-referenced-by-count":6,"title":["Persistent elevation of peripheral blood myeloid cell counts associated with omalizumab therapy"],"prefix":"10.1093","volume":"69","author":[{"given":"Hoan Linh","family":"Banh","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June","family":"Trevoy","sequence":"additional","affiliation":[{"name":"Rehabilitation Medicine, Alberta Health Services, Edmonton"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Pabst","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, University of Alberta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Beach","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, University of Alberta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilini","family":"Vethanayagam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041606593174700_b1-0690302","volume-title":"Xolair (omalizumab) package insert","year":"2010"},{"key":"2019041606593174700_b2-0690302","volume-title":"Xolair (omalizumab) prescribing information","year":"2011"},{"key":"2019041606593174700_b3-0690302","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14712598.7.11.1739","article-title":"Anti-IgE in allergic asthma and rhinitis: an update","volume":"7","author":"Morjaria","year":"2007","journal-title":"Expert Opin Biol Ther."},{"key":"2019041606593174700_b4-0690302","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1164\/ajrccm.155.6.9196082","article-title":"The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects","volume":"155","author":"Fahy","year":"1997","journal-title":"Am J Respir Crit Care Med."},{"key":"2019041606593174700_b5-0690302","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1164\/ajrccm.155.6.9196083","article-title":"Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response","volume":"155","author":"Boulet","year":"1997","journal-title":"Am J Respir Crit Care Med."},{"key":"2019041606593174700_b6-0690302","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.1991.tb37960.x","article-title":"The role of basophils in asthma","volume":"629","author":"Lichtenstein","year":"1991","journal-title":"Ann N Y Acad Sci."},{"key":"2019041606593174700_b7-0690302","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2009.01.041","article-title":"Advances in mechanisms of asthma, allergy, and immunology in 2008","volume":"123","author":"Boyce","year":"2009","journal-title":"J Allergy Clin Immunol."},{"key":"2019041606593174700_b8-0690302","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJM197505292922204","article-title":"Total eosinophil counts in the management of bronchial asthma","volume":"292","author":"Horn","year":"1975","journal-title":"N Engl J Med."},{"key":"2019041606593174700_b9-0690302","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJM199010113231505","article-title":"Eosinophilic inflammation in asthma","volume":"323","author":"Bousquet","year":"1990","journal-title":"N Engl J Med."},{"key":"2019041606593174700_b10-0690302","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0091-6749(90)90090-Q","article-title":"Eosinophils and T- lymphocytes in late-phase allergic reactions","volume":"85","author":"Frew","year":"1990","journal-title":"J Allergy Clin Immunol."},{"key":"2019041606593174700_b11-0690302","volume-title":"BLA STN 103976\/0, review of clinical safety data: original BLS submitted on June 2, 2000 and response to complete review letter submitted on December 18, 2002","author":"Center for Biologics Evaluation and Research, Food and Drug Administration","year":"2003"},{"key":"2019041606593174700_b12-0690302","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","article-title":"Safety and tolerability of omalizumab","volume":"39","author":"Corren","year":"2009","journal-title":"Clin Exp Allergy."},{"key":"2019041606593174700_b13-0690302","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1183\/09031936.02.00278102","article-title":"Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma","volume":"20","author":"Buhl","year":"2002","journal-title":"Eur Respir J."},{"key":"2019041606593174700_b14-0690302","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1378\/chest.10-1194","article-title":"Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review","volume":"139","author":"Rodrigo","year":"2011","journal-title":"Chest."},{"key":"2019041606593174700_b15-0690302","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1385\/CRIAI:29:1:031","article-title":"Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody","volume":"29","author":"Deniz","year":"2005","journal-title":"Clin Rev Allergy Immunol."},{"key":"2019041606593174700_b16-0690302","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1517\/14712598.2010.526103","article-title":"Omalizumab for pediatric asthma","volume":"10","author":"Townley","year":"2010","journal-title":"Expert Opin Biol Ther."},{"key":"2019041606593174700_b17-0690302","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14740338.2011.563840","article-title":"Safety of omalizumab in asthma","volume":"10","author":"Tan","year":"2011","journal-title":"Expert Opin Drug Saf."},{"key":"2019041606593174700_b18-0690302","unstructured":"Food and Drug Administration. Infliximab, etanercept and adalimumab label information. www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm (accessed 2010 Jul 7)."},{"key":"2019041606593174700_b19-0690302","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1164\/rccm.200607-995OC","article-title":"The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease","volume":"175","author":"Rennard","year":"2007","journal-title":"Am J Respir Crit Care Med."},{"key":"2019041606593174700_b20-0690302","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.21869","article-title":"Solid malignancies among patients in the Wegener\u2019s Granulomatosis Etanercept Trial","volume":"54","author":"Stone","year":"2006","journal-title":"Arthritis Rheum."},{"key":"2019041606593174700_b21-0690302","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer."},{"key":"2019041606593174700_b22-0690302","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum."},{"key":"2019041606593174700_b23-0690302","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease","volume":"44","author":"Mackey","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2019041606593174700_b24-0690302","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum."},{"key":"2019041606593174700_b25-0690302","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA."},{"issue":"(suppl 1)","key":"2019041606593174700_b26-0690302","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1093\/annonc\/mdl444","article-title":"Normal and malignant hematopoiesis","volume":"18","author":"Fey","year":"2007","journal-title":"Ann Oncol."},{"key":"2019041606593174700_b27-0690302","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/clim.1999.4799","article-title":"Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)","volume":"93","author":"Conley","year":"1999","journal-title":"Clin Immunol."},{"key":"2019041606593174700_b28-0690302","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1006\/clim.1999.4725","article-title":"Common variable immunodeficiency: clinical and immunological features of 248 patients","volume":"92","author":"Cunningham-Rundles","year":"1999","journal-title":"Clin Immunol."},{"key":"2019041606593174700_b29-0690302","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2010-01-254417","article-title":"How I treat common variable immune deficiency","volume":"116","author":"Cunningham-Rundles","year":"2010","journal-title":"Blood."},{"key":"2019041606593174700_b30-0690302","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s10875-007-9075-1","article-title":"Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency","volume":"27","author":"Quinti","year":"2007","journal-title":"J Clin Immunol."},{"key":"2019041606593174700_b31-0690302","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0016-5085(95)90464-6","article-title":"Orthotopic liver transplantation for chronic hepatitis in two patients with common variable immunodeficiency","volume":"108","author":"Smith","year":"1995","journal-title":"Gastroenterology."},{"key":"2019041606593174700_b32-0690302","unstructured":"Food and Drug Administration. Tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) August 2009. www.fda.gov\/safety\/medwatch\/safetyinformation\/safetyalertsforhumanmedicalproducts\/ucm175843.htm (accessed 2011 Jul 18)."},{"key":"2019041606593174700_b33-0690302","unstructured":"Possible association of Remicade (infliximab) with hepatosplenic T-cell lymphoma in pediatric and young adult patients with Crohn\u2019s disease\u2014for the public. www.hc-sc.gc.ca\/dhp-mps\/medeff\/advisories-avis\/public\/_2006\/remicade_3_pc-cp-eng.php (accessed 2011 Jul 18)."},{"key":"2019041606593174700_b34-0690302","unstructured":"National Institutes of Health. A study of Xolair to evaluate effectiveness and long-term safety in patients with moderate to severe asthma. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00252135?term=EXCELS&rank=2 (accessed 2011 Jul 18)."},{"key":"2019041606593174700_b35-0690302","unstructured":"Food and Drug Administration. Cancer warnings required for TNF blockers. www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm175803.htm (accessed 2011 Jul 18)."},{"key":"2019041606593174700_b36-0690302","volume-title":"Compendium of pharmaceuticals and specialties"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/4\/302\/28455571\/ajhp0302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T11:00:08Z","timestamp":1555412408000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/4\/302\/5112093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,2,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110277","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,2,15]]},"published":{"date-parts":[[2012,2,15]]}}}